Oral administration of the CCR5 inhibitor, maraviroc, blocks HIV Ex vivo infection of langerhans cells within the epithelium

Journal of Investigative Dermatology

Volumn 133, Issue 12, 2013, Pages 2803-2805

  Matsuzawa, Takamitsu ^a   Kawamura, Tatsuyoshi ^a   Ogawa, Youichi ^a   Takahashi, Masaaki ^b   Aoki, Rui ^a   Moriishi, Kohji ^a   Koyanagi, Yoshio ^c   Gatanaga, Hiroyuki ^d   Blauvelt, Andrew ^e   Shimada, Shinji ^a  

^a UNIVERSITY OF YAMANASHI   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

^c KYOTO UNIVERSITY   (Japan)

^d NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^e OREGON MEDICAL RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR5; MARAVIROC;

CD4+ T LYMPHOCYTE; DRUG BLOOD LEVEL; DRUG TISSUE LEVEL; EPIDERMIS; EPITHELIUM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LANGERHANS CELL; LETTER; POST EXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; VIRUS TRANSMISSION;

EID: 84887823149     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2013.215     Document Type: Letter

References (14)

1. Cohen MS, Chen YQ, McCauley M et al. (2011) Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 365: 493-505
2. Dumond JB, Patterson KB, Pecha AL et al. (2009) Maraviroc concentrates in the cervicovaginal fluid and vaginal tissue of HIV-negative women. J Acquir Immune Defic Syndr 51:546-53
3. Ganor Y, Zhou Z, Tudor D et al. (2010) Within 1 h, HIV-1 uses viral synapses to enter efficiently the inner, but not outer, foreskin mucosa and engages Langerhans-T cell conjugates. Mucosal Immunol 3:506-22
4. Grant RM, Lama JR, Anderson PL et al. (2010) Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 363:2587-99
5. Hu J, Gardner MB, Miller CJ (2000) Simian immunodeficiency virus rapidly penetrates the cervicovaginal mucosa after intravaginal inoculation and infects intraepithelial dendritic cells. J Virol 74: 6087-95
6. Kawamura T, Bruse SE, Abraha A et al. (2004) PSCRANTES blocks R5 human immunodeficiency virus infection of Langerhans cells isolated from individuals with a variety of CCR5 diplotypes. J Virol 78:7602-9
7. Kawamura T, Cohen SS, Borris DL et al. (2000) Candidate microbicides block HIV-1 infection of human immature Langerhans cells within epithelial tissue explants. J Exp Med 192:1491-500
8. Lederman MM, Offord RE, Hartley O (2006) Microbicides and other topical strategies to prevent vaginal transmission of HIV. Nat Rev Immunol 6:371-82
9. Ogawa Y, Kawamura T, Matsuzawa T et al. (2013) Antimicrobial Peptide LL-37 Produced by HSV-2-Infected Keratinocytes Enhances HIV Infection of Langerhans Cells. Cell Host Microbe 13:77-86
10. Patterson KB, Prince HA, Kraft E et al. (2011) Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission. Sci Transl Med 3:112re4
11. Takahashi M, Hirano A, Okubo N et al. (2010) Development and application of a simple LCMS method for the determination of plasma maraviroc concentrations. J Med Invest 57:245-50
12. Van der Straten A, Van Damme L, Haberer JE et al. (2012) Unraveling the divergent results of preexposure prophylaxis trials for HIV prevention. AIDS 26:F13-9
13. Veazey RS, Ketas TJ, Dufour J et al. (2010) Protection of rhesus macaques from vaginal infection by vaginally delivered maraviroc, an inhibitor of HIV-1 entry via the CCR5 coreceptor. J Infect Dis 202:739-44
14. Veazey RS, Springer MS, Marx PA et al. (2005) Protection of macaques from vaginal SHIV challenge by an orally delivered CCR5 inhibitor. Nat Med 11:1293-4